Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
5. AcelRx touts Dsuvia data for burn victims
AcelRx Pharmaceuticals said today that it plans to present data from a study evaluating its Dsuvia pain reliever in patients with moderate-to-severe acute pain resulting from trauma or injury.
The company’s Dsuvia candidate is composed of 30 sufentanil tablets delivered sublingually using a disposable, pre-filled single-dose applicator. Dsuvia is investigational and not approved in any country. Read more
4. Medtronic launches DxTerity, TRA-line of radial access devices for PCIs
Medtronic today announced a slew of new percutaneous coronary intervention devices it added to its portfolio, including the DxTerity diagnostic angiography catheter line, the DxTerity TRA, InTRAkit transradial devices and the TRAcelet compression device.
The Fridley, Minn.-based company said all of the items have already received FDA clearance in the US and CE Mark approval in the European Union for use in diagnostic cardiac catheterization procedures and percutaneous coronary interventions. Read more
3. HeartFlow wins nod from U.K. healthcare board
The U.K.’s National Institute for Health & Care Excellence issued final guidance on HeartFlow‘s FFRct technology, which uses algorithms to generate 3D models of blood flows and can help diagnose heart disease.
The British agency recommended the use of FFRct for patients with stable, recent-onset chest pain, finding that the technology is safe, has a high level of diagnostic accuracy and may avoid the need for invasive coronary angiography. Compared to all other tests, FFRct could save the U.K.’s National Health Service roughly £214 ($267) per patient by avoiding unneeded tests and treatment, HeartFlow said today. Read more
2. Allergan acquires Zeltiq Aesthetics in $2.48B deal
Allergan said today that it will pay $2.48 billion for Zeltiq Aesthetics Inc. and its portfolio of body-contouring products.
Zeltiq’s FDA-approved CoolSculpting system uses a cooling mechanism to reduce the appearance of fat which has not responded to diet or exercise, without disturbing surrounding tissue. Read more
1. Medtronic debuts outcomes training program for EMEA
Medtronic said today that it’s launching a outcomes-based training program in Europe, the Middle East & Africa that aims to reach 500,000 healthcare providers over the next 5 years.
It’s part of the push toward “value-based healthcare” for the world’s largest pure-play medical device maker, which chairman & CEO Omar Ishrak has championed for years. The new program, Medtronic Impact, goes beyond traditional training on products and procedures, the Fridley, Minn.-based company said. Read more
